Table 1.

Clinical characteristics of the study cohorts.

Characteristic	Subgroup	Turku	Charité 1	Charité 2	Charité 3
Malignant (N)		197	51	104	147
Age (years)		66 (59–72)	61 (56–68)	65 (57–70)	59 (50–67)
Histology	Serous	156	48	95	147
	Mucinous	13		1
	Endometroid	16	1	2
	Clear-cell	12		1
	Other/unknown		2	5
Stage	I	31			2
	II	12		1	5
	III	102	51	67	99
	IV	50		24	31
	NA	2		12	10
Follow-up time (years)	Death	2.6 (1.5–3.9)	3.6 (1.9–6.0)	1.6 (0.9–2.3)	3.2 (1.7–4.3)
	Progression	1.3 (0.8–2.2)	2.0 (1.0–3.6)	1.2 (0.8–1.8)	1.5 (0.8–2.8)
Benign (N)		114			98
Age (years)		55 (45-68)			41 (31–55)